|
Oct 1
|
Pfizer Raises $3.2 Billion by Selling Part of Haleon Stake
|
|
Oct 1
|
Why Are Analysts Bullish On Pfizer Inc. (PFE) Right Now?
|
|
Oct 1
|
Pfizer to Receive 2.66 Billion Pounds From Haleon in Share Deal
|
|
Oct 1
|
Pfizer offloads $3.3 billion stake in Sensodyne-maker Haleon
|
|
Sep 30
|
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
|
|
Sep 30
|
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
|
|
Sep 30
|
Drug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon
|
|
Sep 29
|
Here is What Jim Cramer Likes Pfizer Inc. (NYSE:PFE)
|
|
Sep 28
|
3 Surprisingly Underrated Stocks to Buy Right Now
|
|
Sep 27
|
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
|
|
Sep 27
|
PFE vs. NVO: Which Stock Is the Better Value Option?
|
|
Sep 27
|
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
|
|
Sep 27
|
4 High Earnings Yield Stocks That Value Investors Should Buy Now
|
|
Sep 27
|
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
|
|
Sep 26
|
Pfizer (PFE) Rises But Trails Market: What Investors Should Know
|
|
Sep 26
|
Pfizer Sickle Cell Drug Suspended by Europe in New Setback
|
|
Sep 26
|
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
|
|
Sep 26
|
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
|
|
Sep 26
|
Pfizer’s Strategy Looks Shakier After Sickle-Cell Disappointment
|
|
Sep 26
|
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
|